Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions about your mental health treatment.
Major depressive disorder (MDD) affects millions of people in the United States, yet for a significant number, standard antidepressants don’t provide the relief they need. About one in three people with major depression develops treatment-resistant depression (TRD). TRD generally refers to depression that does not respond after at least two appropriately prescribed antidepressant treatments. However, definitions can differ across clinical practice.
When that happens, the conversation about ketamine vs. antidepressants often begins.
This isn’t a simple either/or choice. Both have a defined role in depression care. But understanding their differences, and when one is clearly better suited than the other, can help you have a more productive conversation with your doctor about what comes next.
How Do Ketamine and Antidepressants Work Differently?
To understand why this comparison matters, it helps to start by looking at how each type of medication works in the brain.
| Traditional Antidepressants | Ketamine | |
| Drug classes |
|
|
| Primary target | Monoamine system: increases the availability of serotonin, norepinephrine, or both | NMDA receptors in the brain’s glutamate system: the primary excitatory neurotransmitter pathway |
| Mechanism | Corrects monoamine deficits through reuptake inhibition or enzyme blockade over time | Blocks NMDA receptors and activates the glutamatergic system.
Research in Neuropsychopharmacology suggests that downstream effects on BDNF signaling support new neural connections and synaptic plasticity, though the precise mechanism in humans remains an active area of investigation. |
| Speed of onset | 4–6 weeks for meaningful symptom improvement | Hours: NIH research confirms depressive symptoms can improve within hours of a single administration |
| Who it is for | First-line treatment for most patients with depression | Primarily for patients who have not reached remission after sequential medication trials, which is why augmentation, neuromodulation, and ketamine are considered |
| Originally developed as | Purpose-built antidepressants (various decades) | Dissociative anesthetic: its antidepressant use is off-label for IV ketamine; esketamine is FDA-approved for TRD and MDD with acute suicidal ideation |
Ketamine for Treatment-Resistant Depression: What the Evidence Shows
When standard antidepressant treatments have already failed, ketamine has strong, well-documented clinical evidence supporting its use.
Key Clinical Findings
- Ketamine vs. ECT: A study found that ketamine was noninferior to electroconvulsive therapy (ECT) for reducing depressive symptoms in adults. This is with treatment-resistant depression without psychotic features who had been referred for ECT. In other words, ketamine produced symptom improvement that was comparable to ECT in this specific patient group. However, differences in durability, side effects, and individual suitability remain important when choosing between treatments.
- Broader TRD populations: A meta-analysis in eClinicalMedicine (The Lancet) confirmed meaningful antidepressant effects from both ketamine and esketamine in TRD populations. It includes those with bipolar depression, with outcomes improving under sufficient dosing protocols.
How Ketamine Is Administered
- IV infusion: Racemic ketamine is given at subanesthetic doses over approximately 40 minutes, far below doses used in surgical anesthesia. This is an off-label use; IV ketamine has no FDA approval for any psychiatric indication.
- Intranasal (Spravato®): Esketamine nasal spray is FDA-approved (2019) for adults with TRD in conjunction with an oral antidepressant. In 2020, approval was expanded to include depressive symptoms in adults with MDD and acute suicidal ideation or behavior, also alongside an oral antidepressant and under REMS supervision.
Important Regulatory Notes
- The FDA has not established that esketamine prevents suicide or reduces suicidal ideation or behavior. Its approved indication is for depressive symptoms in this population. It is not a substitute for comprehensive crisis care.
- The FDA has issued specific warnings about compounded ketamine products (oral, intranasal, and other forms produced outside regulated manufacturing). These are not FDA-approved, have not been evaluated for psychiatric use, and carry additional risks when used without clinical supervision.
How Does Ketamine Depression Treatment Compare to Conventional Antidepressants?
The two treatment methods differ across several practical dimensions. Here’s what the clinical evidence shows:
Speed of Action
This is the most significant difference. Ketamine provides rapid relief, reducing depressive symptoms within hours of the first infusion. Standard antidepressant treatments typically require several weeks before producing noticeable changes in mood.
For someone experiencing severe symptoms or at elevated risk of suicide, that gap can be life-altering.
Who Responds
Medications work differently for different people. Many patients improve with first-line antidepressants, but not everyone reaches full remission. In general, the likelihood of improvement becomes lower with each additional medication trial.
Ketamine is most often studied and used for patients whose symptoms have not improved enough with standard antidepressants. In these treatment-resistant cases, retrospective clinical data suggest that about 44% of patients show a meaningful response after a series of six IV ketamine infusions.
This offers partial symptom relief for many individuals who have already tried multiple treatments without success.
Duration of Effect
Traditional medications are designed for daily, long-term use and maintain their antidepressant effects as long as the patient continues taking them. After a single infusion, ketamine’s antidepressant benefits typically diminish within several days to one week, though there is considerable variability between individuals.
After a full series of infusions, the median time to relapse is approximately 18 days, which is why ongoing maintenance sessions are typically required. When ketamine maintenance is stopped, the antidepressant effect gradually fades. This is worth discussing with your provider before starting.
Side Effects
Traditional antidepressants commonly cause weight gain, sexual dysfunction, emotional blunting, and sleep disturbances. Ketamine’s most frequently reported side effects, such as dissociation, temporary blood pressure elevation, and nausea, are generally limited to the period around each treatment session.
The risk of ketamine misuse is a real consideration. That’s why both IV ketamine and FDA-approved esketamine require clinical supervision rather than at-home use.
Access and Cost
Traditional antidepressants are widely available, typically covered by most insurance plans, and taken at home.
IV ketamine is administered in a clinic under medical supervision and often requires out-of-pocket payment, though coverage is expanding. Esketamine (Spravato®) must be dispensed and administered only in a certified healthcare setting enrolled in the REMS program. Patients should also be monitored for at least 2 hours post-dose, as required by the FDA label. Insurance coverage for both forms varies considerably by provider and location.
With these trade-offs in mind, the comparison leads naturally to the question most people managing depression are asking.
Is Ketamine Better Than Antidepressants? It Depends on Where You Are in Treatment
Ketamine is not a replacement for first-line antidepressants. Instead, it is a targeted option used in specific clinical situations. The American Journal of Psychiatry notes that ketamine’s role in depression treatment is still evolving. Clinical guidelines generally reserve it for patients who have not responded sufficiently to standard first-line therapies.
Because the evidence base is still developing, guideline recommendations are typically described as weak or conditional. This means ketamine can be appropriate for some patients, but decisions should be individualized and made with a qualified clinician.
Someone Newly Diagnosed
For someone newly diagnosed who hasn’t yet tried medication, SSRIs or SNRIs remain the recommended starting point. They’re better studied for long-term use in managing affective disorders and far more accessible to patients seeking treatment for the first time.
Someone With Complete 2 or More Sufficient Medication Trials
For someone who has completed two or more sufficient medication trials without adequate relief, ketamine offers something traditional antidepressants cannot deliver in that timeframe: rapid, validated symptom relief. This is especially true if they’re experiencing suicidal thoughts.
As noted in Biological Psychiatry, ketamine effects are typically seen as soon as 40 minutes after IV infusion. For many patients, that window of stability makes it possible to reengage with therapy, rebuild routines, and establish a longer-term mental health plan. Some early research also suggests that ketamine may support mood regulation and show promise for anxiety disorder symptoms. However, its primary and most established evidence base remains in TRD.
Who Should Consider Ketamine Treatment?
Based on current clinical guidelines, ketamine is generally considered a suitable option for patients who meet the following criteria:
- Failed to respond sufficiently to at least two antidepressant trials at an appropriate dose and duration
- Are experiencing active suicidal ideation requiring rapid intervention
- Have moderate to severe depression confirmed by clinical assessment
- Do not have a history of psychosis (which can worsen with ketamine), active substance use disorder, or uncontrolled cardiovascular conditions (due to ketamine’s temporary blood pressure effects)
A thorough review of your medical history and a full psychiatric evaluation are essential before starting ketamine treatment. A qualified healthcare provider will assess whether it’s appropriate given your specific diagnosis and prior medication management history.
For those who do qualify, the next question is often about what long-term treatment actually looks like.
What Are the Limits of Long-Term Ketamine Use?
Research is still catching up to clinical demand in this area.
Key points to know:
Regulatory Status
A 2024 guideline review (PMC) confirms IV ketamine is the current evidence-based standard for off-label TRD use, but none of the racemic ketamine delivery routes have received formal regulatory approval as a long-term psychiatric treatment.
Compounded Ketamine
The FDA has specifically warned that compounded ketamine products are not FDA-approved and present additional risks. This is especially true when used outside of supervised clinical settings.
Esketamine (Spravato®) Maintenance Schedule (FDA Label Guidance)
- Weeks 1–4: Twice weekly
- Weeks 5–8: Once weekly
- Week 9 onward: Once weekly or once every two weeks, based on response
- Benefit is reassessed after the initial four weeks
Even with a structured schedule, questions about long-term dependence, the durability of effects, and interactions with other treatments require consistent oversight from a licensed provider.
So, Which One Is Right for You?
First-line antidepressants remain the right starting point for most people with depression. For those who haven’t found sufficient relief after multiple medication trials, ketamine depression treatment offers a clinically validated, fast-acting option. This addresses a gap that standard antidepressant treatments cannot fill, particularly for those with treatment-resistant depression or active suicidal ideation.
The goal isn’t to choose one over the other permanently. It’s to find the right approach for where you are right now. If you’ve been diagnosed with this condition, speak with a psychiatrist or mental health specialist about whether ketamine or esketamine belongs in your care plan.
Explore What’s Actually Working for Your Depression at Serenity
At Serenity Mental Health Centers, we’ve been helping people move beyond treatment-resistant depression since 2017, with evidence-based treatments tailored to each individual, not one-size-fits-all approaches. Our psychiatrists stay current with advances in mental health care. These include ketamine therapy, so you always have access to the most current, effective options available.
When you come to Serenity, you receive a personalized treatment plan tailored to your history, concerns, and goals. You work one-on-one with a dedicated psychiatrist who takes the time to truly understand your experience. With clinics across the United States, that level of care is closer than you think.
Request an Appointment Today. Take the first step toward a plan that’s built around you.